Trial · NCT02654639
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 21
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Hepatobiliary disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Diarrhea | Gastrointestinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Neutrophil count decreased | Immune system disorders | TAS-102 and Bevacizumab | 2 | 4 | 4 |
| other | Pain | General disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Vomiting | Gastrointestinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Fatigue | General disorders | TAS-102 and Bevacizumab | 2 | 4 | 2 |
| other | Nervous system disorders - Other | Nervous system disorders | TAS-102 and Bevacizumab | 1 | 4 | 2 |
| other | Hepatic failure | Hepatobiliary disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Constipation | Gastrointestinal disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Dry skin | Skin and subcutaneous tissue disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Dysgeusia | Skin and subcutaneous tissue disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Hypoalbuminemia | Hepatobiliary disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Hyponatremia | Blood and lymphatic system disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Nail discoloration | Skin and subcutaneous tissue disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | Peripheral sensory neuropathy | Nervous system disorders | TAS-102 and Bevacizumab | 1 | 4 | 2 |
| other | Skin hyperpigmentation | Skin and subcutaneous tissue disorders | TAS-102 and Bevacizumab | 1 | 4 | 1 |
| other | White blood cell decreased | Immune system disorders | TAS-102 and Bevacizumab | 1 | 4 | 3 |
| serious | Neutropenia | Immune system disorders | TAS-102 and Bevacizumab | 1 | 4 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02654639/events